On August 27, 2026 SL Science Holding Limited ("SL Science" or the "Company") (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in innovative cellular and gene therapies, reported the filing of a new Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA). The DMF, filed under number 044612, covers exosomes derived from Gamma Delta T (GDT) cells. It was filed by JY BioMed Co., Ltd. ("JY BioMed"), the intellectual property holder of the GDT platform and SL Science’s licensor.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This filing marks a significant milestone, as it extends the FDA-filed manufacturing and quality documentation across two formats of the same core technology: the GDT cells themselves, and the cell-free exosomes those cells secrete. A DMF streamlines future regulatory processes by providing the FDA with confidential chemistry, manufacturing, and controls (CMC) data that can be referenced in subsequent applications. Because CMC requirements are frequently a major bottleneck in cell therapy development, having this documentation already on file is expected to significantly reduce the groundwork required for downstream programs.
The cell-free exosome format also addresses a critical delivery challenge in oncology. Published preclinical research demonstrates that GDT-derived exosomes carry proteins capable of both directly triggering tumor cell death and stimulating the host’s own immune system. Furthermore, independent studies indicate these exosomes can work synergistically with radiotherapy and remain active in immunosuppressive tumor environments.
Crucially for SL Science’s focus on brain cancer, this format offers a potential solution to a well-known biological barrier. As the Company’s leadership recently highlighted in peer-reviewed literature, the primary constraint in treating glioblastoma is successfully delivering therapies across the blood-brain barrier. Unlike larger cells, extracellular vesicles such as exosomes have been shown in independent studies to actively cross an intact blood-brain barrier, reaching the central nervous system through a receptor-mediated biological route.
"What accumulates around a platform matters as much as the platform itself," said Mr. William Wang, Chairman and Chief Executive Officer of SL Science. "There is now manufacturing and quality documentation on file with the FDA for both the GDT cells and the exosomes those cells secrete – work no downstream program has to do again. And in brain cancer, where getting an effector to the tumor is the problem we ourselves have written about, a format that reaches the central nervous system by an active biological route is worth understanding properly."
(Press release, SL Science, AUG 27, 2026, View Source [SID1234670400])